For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Agilon Health Inc (NYSE: AGL) closed at $1.27 down -0.78% from its previous closing price of $1.28. In other words, the price has decreased by -$0.78 from its previous closing price. On the day, 4.05 million shares were traded. AGL stock price reached its highest trading level at $1.3 during the session, while it also had its lowest trading level at $1.25.
Ratios:
For a deeper understanding of Agilon Health Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.16. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.02.
On August 06, 2025, Citigroup Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $1. Citigroup Upgraded its Neutral to Buy on April 25, 2025, while the target price for the stock was maintained at $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 13 ’24 when McLoughlin Karen bought 25,000 shares for $2.20 per share. The transaction valued at 55,085 led to the insider holds 73,166 shares of the business.
Battaglia Silvana bought 25,062 shares of AGL for $50,269 on Dec 11 ’24. The Director now owns 66,144 shares after completing the transaction at $2.01 per share. On Nov 25 ’24, another insider, MCKENZIE DIANA, who serves as the Director of the company, bought 12,500 shares for $2.28 each. As a result, the insider paid 28,474 and bolstered with 51,319 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGL now has a Market Capitalization of 526317216 and an Enterprise Value of 240689392. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.09 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at 0.041 whereas that against EBITDA is -0.693.
Stock Price History:
The Beta on a monthly basis for AGL is 0.12, which has changed by -0.69544363 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, AGL has reached a high of $6.08, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is -27.39%, while the 200-Day Moving Average is calculated to be -53.74%.
Shares Statistics:
For the past three months, AGL has traded an average of 9.38M shares per day and 6117600 over the past ten days. A total of 414.28M shares are outstanding, with a floating share count of 304.05M. Insiders hold about 26.63% of the company’s shares, while institutions hold 77.89% stake in the company. Shares short for AGL as of 1755216000 were 19114563 with a Short Ratio of 2.04, compared to 1752537600 on 17820027. Therefore, it implies a Short% of Shares Outstanding of 19114563 and a Short% of Float of 7.539999999999999.
Earnings Estimates
As of right now, 10.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.08 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$0.34 and -$0.89 for the fiscal current year, implying an average EPS of -$0.52. EPS for the following year is -$0.38, with 14.0 analysts recommending between -$0.16 and -$0.53.
Revenue Estimates
A total of 17 analysts believe the company’s revenue will be $1.43B this quarter.It ranges from a high estimate of $1.53B to a low estimate of $1.35B. As of the current estimate, Agilon Health Inc’s year-ago sales were $1.45BFor the next quarter, 17 analysts are estimating revenue of $1.47B. There is a high estimate of $1.56B for the next quarter, whereas the lowest estimate is $1.4B.
A total of 19 analysts have provided revenue estimates for AGL’s current fiscal year. The highest revenue estimate was $6.02B, while the lowest revenue estimate was $5.7B, resulting in an average revenue estimate of $5.82B. In the same quarter a year ago, actual revenue was $6.06BBased on 19 analysts’ estimates, the company’s revenue will be $6.28B in the next fiscal year. The high estimate is $7.14B and the low estimate is $5.77B.
